GlassScriptPhysician profile
Robert L Stanley
NPI 1114903879
$3,647.09
in general payments reported to CMS, 2019-2025
25 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $706 · 2021: $382 · 2022: $648 · 2023: $679 · 2024: $284 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,132.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $635.02 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $481.61 | 2021-2024 | Freestyle Libre 3 |
| Amgen INC. | $405.10 | 2019-2024 | Prolia, Evenity, Otezla |
| Astrazeneca Pharmaceuticals LP | $356.11 | 2019-2024 | Airsupra |
| Abbvie INC. | $314.30 | 2022-2025 | Vraylar |
| Novo Nordisk INC | $267.94 | 2019-2022 | |
| Pfizer INC. | $181.36 | 2020-2025 | |
| Astellas Pharma US INC | $160.64 | 2019-2023 | Veozah |
| Lilly USA, LLC | $138.84 | 2019-2025 | Mounjaro, Amyvid, Zepbound |
| Merck Sharp & Dohme LLC | $115.84 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $115.66 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $70.96 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $66.89 | 2019-2024 | |
| Amarin Pharma, INC. | $52.47 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $40.06 | 2019-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $37.23 | 2020 | |
| Radius Health, INC. | $36.69 | 2019 | |
| Eisai INC. | $34.14 | 2020-2023 | |
| Shield Therapeutics INC | $33.40 | 2025 | |
| Abiomed | $32.22 | 2024 | Impella |
| Sanofi Pasteur INC. | $17.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.78 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.34 | 2023 | Quviviq |
| Allergan, INC. | $12.16 | 2020 | |
| Esperion Therapeutics, INC. | $11.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stanley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.